Kriya Therapeutics is a next-generation gene therapy company focused on designing and developing transformative gene therapies for highly prevalent serious diseases.
Kriya's mission is to expand the reach of gene therapy to address highly prevalent diseases affecting millions of patients.
Kriya Therapeutics was founded in 2019 by Shankar Ramaswamy, Roger Jeffs and John Fraser Wright. The company is headquartered in Palo Alto, California.
Kriya is built on two distinct technology platforms: its computationally enabled proprietary platform for rational vector design (SIRVE™) and its innovative high-efficiency manufacturing platform for scalable and low-cost production (STRIPE™).
Kriya's STRIPE is being developed at Kriya’s 51,000 square foot manufacturing facility in Research Triangle Park, North Carolina, and can support simultaneous manufacturing of multiple products from early research through commercialization.
Kriya is advancing a deep and diversified pipeline of innovative gene therapies spanning rare and prevalent diseases in multiple therapeutic verticals, with current pipeline programs addressing metabolic, ophthalmic and oncologic diseases.
Kriya is backed by Patient Square Capital, QVT, Dexcel Pharma, Foresite Capital, Woodline Partners LP, Bluebird Ventures, Amplo, and others. The company closed a $100M Series B round on Jul 14, 2021. This brings Kriya's total funding to $180.5M to date.